Mainz Biomed
Mainz Biomed Launches Study for Colon Cancer Screening Test, Aiming for Added Sensitivity
The firm already markets the assay in Europe, but is planning to begin another study to support adoption in the US, if its current trial is successful.
Mainz Biomed, Thermo Fisher Scientific to Develop Colorectal Cancer Screening Test
The collaboration will enable Mainz Biomed to harness Thermo Fisher’s resources to develop a new version of its mRNA-based colorectal cancer screening test.
Mainz Biomed Stock Spikes on Positive Data for mRNA-Enhanced Colorectal Cancer Screening Assay
In top-line data, Mainz Biomed's enhanced ColoAlert detected CRC with 94 percent sensitivity and 97 percent specificity, and advanced adenoma with 81 percent sensitivity.